Intuitive Surgical, Inc. $ISRG Shares Sold by Cadinha & Co. LLC

Key Points

• Cadinha & Co. cut its Intuitive Surgical stake by 44.2% in the third quarter, selling 22,531 shares and retaining 28,413 shares valued at approximately $11.6 million. Institutional investors still own 83.64% of the company.
• Intuitive Surgical reported strong quarterly results, with revenue up 21.7% year over year to $3.05 billion and EPS of $3.00, beating analysts’ $2.65 estimate. However, profitability faces pressure from a $450 million antitrust settlement and planned price reductions.
• Analysts maintain a broadly positive view, with 24 Buy ratings, six Holds and one Sell, producing a “Moderate Buy” consensus and an average price target of $495.71. The stock’s elevated valuation—around 48 times earnings—leaves it sensitive to any slowdown in procedure growth.

Cadinha & Co. LLC decreased its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 44.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 28,413 shares of the medical equipment provider's stock after selling 22,531 shares during the period. Intuitive Surgical comprises about 1.9% of Cadinha & Co. LLC's holdings, making the stock its 21st largest position. Cadinha & Co. LLC's holdings in Intuitive Surgical were worth $11,554,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also bought and sold shares of the stock. Diligent Investors LLC lifted its holdings in Intuitive Surgical by 2.2% during the third quarter. Diligent Investors LLC now owns 2,293 shares of the medical equipment provider's stock valued at $932,000 after purchasing an additional 50 shares during the last quarter. Foster Victor Wealth Advisors LLC boosted its position in Intuitive Surgical by 14.7% during the third quarter. Foster Victor Wealth Advisors LLC now owns 22,749 shares of the medical equipment provider's stock worth $9,855,000 after purchasing an additional 2,915 shares during the period. Bender Robert & Associates increased its stake in shares of Intuitive Surgical by 1.5% in the third quarter. Bender Robert & Associates now owns 69,654 shares of the medical equipment provider's stock worth $28,323,000 after purchasing an additional 1,000 shares in the last quarter. Hartford Financial Management Inc. increased its stake in shares of Intuitive Surgical by 1.7% in the third quarter. Hartford Financial Management Inc. now owns 1,924 shares of the medical equipment provider's stock worth $782,000 after purchasing an additional 32 shares in the last quarter. Finally, White Lighthouse Investment Management Inc. purchased a new position in shares of Intuitive Surgical in the third quarter worth about $819,000. Institutional investors own 83.64% of the company's stock.

Intuitive Surgical Stock Performance

Shares of ISRG stock opened at $443.85 on Friday. The firm has a market cap of $156.80 billion, a P/E ratio of 48.00, a P/E/G ratio of 3.23 and a beta of 1.46. The business's 50 day moving average price is $394.35 and its 200-day moving average price is $408.83. Intuitive Surgical, Inc. has a fifty-two week low of $328.57 and a fifty-two week high of $603.88.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last announced its earnings results on Tuesday, October 20th. The medical equipment provider reported $3.00 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.65 by $0.35. Intuitive Surgical had a return on equity of 18.17% and a net margin of 25.54%. The firm had revenue of $3.05 billion during the quarter, compared to analyst estimates of $2.91 billion. During the same quarter in the prior year, the company earned $2.40 EPS. The business's revenue was up 21.7% compared to the same quarter last year. As a group, equities analysts predict that Intuitive Surgical, Inc. will post 8.87 EPS for the current year.

Insiders Place Their Bets

In other Intuitive Surgical news, Director Gary Guthart sold 10,000 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $400.00, for a total transaction of $4,000,000.00. Following the sale, the director directly owned 1,245,679 shares in the company, valued at approximately $498,271,600. This trade represents a 0.80% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Fredrik Widman sold 1,089 shares of the business's stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $374.44, for a total value of $407,765.16. Following the completion of the transaction, the vice president directly owned 1,026 shares of the company's stock, valued at approximately $384,175.44. This trade represents a 51.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 12,370 shares of company stock worth $4,891,989 in the last three months. Corporate insiders own 0.60% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on ISRG. Wells Fargo & Company reaffirmed an "overweight" rating and issued a $486.00 price target (down from $487.00) on shares of Intuitive Surgical in a report on Wednesday. UBS Group reaffirmed a "buy" rating on shares of Intuitive Surgical in a report on Tuesday, October 13th. Sanford C. Bernstein reaffirmed an "outperform" rating on shares of Intuitive Surgical in a report on Wednesday, August 12th. Oppenheimer reiterated an "outperform" rating and issued a $500.00 target price on shares of Intuitive Surgical in a research note on Wednesday. Finally, KeyCorp reaffirmed an "overweight" rating on shares of Intuitive Surgical in a report on Wednesday, August 12th. Twenty-four analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $495.71.

More Intuitive Surgical News

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Third-quarter revenue rose roughly 22% year over year to about $3.05 billion, while adjusted earnings of $3.00 per share exceeded the $2.65 consensus estimate. Revenue growth was supported by 546 da Vinci system placements, higher procedure volumes and continued international adoption. Intuitive Surgical's Q3 Earnings Beat Estimates on Strong System Sales
• Positive Sentiment: Management maintained a constructive longer-term outlook, highlighting global growth, extended-use instruments and a 2027 product pipeline. Analysts at Stifel Nicolaus, Oppenheimer and Piper Sandler reaffirmed Buy ratings, while JPMorgan raised its price target to $475 and Bank of America maintained a $470 target. Intuitive Surgical Strong Q3 Beat and 2027 Pipeline
• Positive Sentiment: Investor sentiment also benefited from the stock regaining its 200-day moving average, which some technical investors view as a sign of improving long-term momentum. ISRG Crossed Above the 200-Day Moving Average
• Neutral Sentiment: ISRG’s valuation remains demanding, with a price-to-earnings ratio above 50. That leaves the stock sensitive to any signs that growth or procedure momentum could fall short of elevated expectations.
• Negative Sentiment: Quarterly profitability was reduced by a $450 million antitrust settlement charge. In addition, planned instrument and accessory price reductions are expected to lower revenue per procedure by approximately 3% to 5%, creating near-term margin and revenue pressure. Intuitive Surgical Reports Q3 Earnings Impacted by Antitrust Settlement
• Negative Sentiment: The company narrowed its 2026 global da Vinci procedure-growth outlook to roughly 14%–15%, and analysts flagged slowing U.S. procedure growth as a risk to 2027 momentum. RBC nevertheless retained an Outperform rating but reduced its price target to $550, while Mizuho cut its target to $400 and kept a Neutral rating.

About Intuitive Surgical

Intuitive Surgical, Inc develops and manufactures robotic-assisted systems and related technologies for minimally invasive surgery. Its products are designed to help surgeons perform procedures through small incisions while providing enhanced visualization, precision and control. The company's primary platform is the da Vinci Surgical System, which is used across a range of specialties, including urology, gynecology, general surgery, cardiothoracic surgery and other procedures.

The company also offers the Ion endoluminal system, which is designed to support minimally invasive lung biopsy procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.